Your browser doesn't support javascript.
loading
The effects of levetiracetam, sumatriptan, and caffeine in a rat model of trigeminal pain: interactions in 2-component combinations.
Tomic, Maja A; Pecikoza, Uros B; Micov, Ana M; Popovic, Bozidar V; Stepanovic-Petrovic, Radica M.
Afiliação
  • Tomic MA; From the *Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia; and †Faculty of Philosophy, University of Montenegro, Niksic, Montenegro.
Anesth Analg ; 120(6): 1385-93, 2015 Jun.
Article em En | MEDLINE | ID: mdl-25710675
ABSTRACT

BACKGROUND:

Levetiracetam is an antiepileptic drug with analgesic efficacy shown in pain models and small clinical trials. Sumatriptan is used in acute migraine treatment. Caffeine is widely consumed in some beverages/foods and is also an adjuvant in analgesic formulations. We examined the effects of systemic levetiracetam, sumatriptan, and caffeine and their interactions in 2-component combinations in the rat orofacial formalin test, a model of trigeminal pain.

METHODS:

Rats received a subcutaneous injection of formalin solution into the perinasal area, and the total time spent in nociceptive behavior (face rubbing) was quantified. The antinociceptive effect of drugs/drug combinations was assessed 1 hour after per os administration. The type of interaction between levetiracetam/sumatriptan and caffeine was examined by comparing the effects of a fixed, effective dose of levetiracetam/sumatriptan alone with the effects of the same dose applied with increasing, subeffective doses of caffeine. The type of interaction between levetiracetam and sumatriptan was determined by isobolographic analysis.

RESULTS:

Levetiracetam (1-50 mg/kg) and sumatriptan (0.5-5 mg/kg) produced significant and dose-dependent antinociceptive effects in both phases of the orofacial formalin test (P ≤ 0.001). Caffeine (7.5-100 mg/kg) produced significant antinociception in the second phase of the test (P = 0.04). Caffeine (1-7.5 mg/kg) significantly reduced the antinociceptive effects of levetiracetam (25 mg/kg) (first phase P = 0.002, second phase P < 0.001) and sumatriptan (2.5 mg/kg) (first phase P = 0.014, second phase P = 0.027); dose-dependent inhibition was observed in the second phase. Levetiracetam and sumatriptan exerted an additive interaction in the second phase of the orofacial formalin test.

CONCLUSIONS:

Results indicate that levetiracetam may be useful for treatment of pain in the trigeminal region. Dietary caffeine might decrease the effects of levetiracetam and sumatriptan; this needs to be considered in clinical settings. A levetiracetam-sumatriptan combination could also be useful in trigeminal pain treatment. Its efficacy and adverse effects should be examined clinically.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piracetam / Dor Facial / Cafeína / Sumatriptana / Doenças do Nervo Trigêmeo / Neuralgia Facial / Analgésicos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Anesth Analg Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piracetam / Dor Facial / Cafeína / Sumatriptana / Doenças do Nervo Trigêmeo / Neuralgia Facial / Analgésicos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Anesth Analg Ano de publicação: 2015 Tipo de documento: Article